2023 Breakfast Briefings
June 11th, 2023 

Supported through an independent educational grant from Merck.

Abstract Info

Final 7-Year Follow Up and Retreatment Substudy Analysis of Murano: Venetoclax-Rituximab (VenR)-Treated Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL)

Number: S201

Author: Arnon Kater

Abstract (pdf)

Ibrutinib versus Placebo in Patients with Asymptomatic, Treatment-Naïve Early Stage Chronic Lymphocytic Leukemia (CLL): Final Results of the Phase 3, Double-Blind, Placebo-Controlled CLL12 Trial (Petra Langerbeins)

Number: S200

Author: P Langerbeins

Abstract (pdf)

Moderator

Moderator-Ghia

Paolo Ghia, MD, PhD

Full Professor, Medical Oncology

Director, Strategic Research Program on CLL

Deputy Chairman, Experimental Oncology Division Head, B-Cell

Neoplasia Unit

Università Vita-Salute San Raffaele

RCCS Ospedale San Raffaele

Milano, Italy